This page shows the latest oseltamivir news and features for those working in and with pharma, biotech and healthcare.
It has already been shown to be effective against a wide range of flu viruses, including those resistant to Roche’s now off-patent and former blockbuster flu treatment, Tamiflu (oseltamivir).
oseltamivr. The approval was based on results from Roche’s phase 3 CAPSTONE-2 trial of Xofluza, compared to oseltamivir or placebo, in people aged 12 or over, who met the ... However, similar efficacy results were seen between Xofluza and oseltamivir
It applies mainly to hormone replacement therapies but also includes all adrenaline pens, hepatitis B vaccines and the influenza drug oseltamivir, sold by Roche as Tamiflu, amongst other drugs.
It has already been shown to be effective against a wide range of flu viruses, including those resistant to Roche’s now off-patent and former blockbuster flu treatment, Tamiflu (oseltamivir). ... Roche is keen to produce more evidence of the
Xofluza significantly reduced the duration of flu symptoms compared to placebo, and demonstrated similar efficacy compared to oseltamivir. ... Analysts say the new treatment will have to generate more evidence of significant benefits in these high risk
Analysts say the new treatment will have to generate more evidence of significant benefits in these high risk groups in order for healthcare systems to switch away from generic oseltamivir.
More from news
Approximately 0 fully matching, plus 35 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...